卡维地洛对非梗阻性肥厚型心肌病患者心室重构的影响  

Effects of Carvedilol on Ventricular Remodeling in Patients with Hypertrophic Non-obstructive Cardiomyopathy

作　　者：段班燕[1] 何圆圆[2] 党书毅[1] 周明[1] 王俊峰[1] 

机构地区：[1]湖北医药学院附属十堰市太和医院心内科,442000 [2]湖北医药学院附属十堰市太和医院血液科,442000

出　　处：《医学研究杂志》2013年第8期133-135,共3页Journal of Medical Research

摘　　要：目的观察卡维地洛对肥厚型心肌病患者心室重构的影响。方法将35例肥厚型心肌病患者随机分为卡维地洛组(21例)与对照组(14例),两组均予常规治疗,卡维地洛组加用卡维地洛,疗程4个月,并随访至半年。检测两组治疗前后氧化应激、炎症、超声及基质金属蛋白酶2(MMP-2)和特异性组织抑制剂2(TIMP-2)的改变情况以及半年内的不良心血管事件。结果治疗后两组氧化应激、炎症均较治疗前显著降低,心室重构减缓(P<0.05),而卡维地洛组尤为明显(P<0.01)。相比对照组,卡维地洛组的半年心血管不良事件更低(P<0.05)。结论卡维地洛可降低氧化应激、炎症,减缓肥厚型心肌病患者心室重构,减少心血管不良事件的发生。Objective To investigate the effects of carvedilol on ventricular remodeling in patients with hypertrophic non - obstruc- tive eardiomyopathy （HNCM）. Methods Totally 35 patients with HNCM were randomly divided into the carvedilol group （n = 21） and the control group（ n = 140）. Each group was given traditional treatment while the carvedilol group was additionally treated with carvedilol for 4 months. The oxidative stress, inflammatory markers, echocardiography, matrix metalloproteinase 2 （MMP- 2）, tissue inhibits of metalloproteinase - 2 （TIMP - 2） were detected in both groups before and after treatment. All patients were followed up to 6 months. Re- suits After treatment, the oxidative stress, serum level of inflammatory cytokines and ventricular remodeling were improved （P 〈 0. 05） , especially in the carvedilol group （P 〈 0. 01 ）. Compared to the control group, lower cardiovascular adverse events were occurred in the carvedilol group （P 〈 0.05）. Conclusion Carvedilol can lower oxidative stress, serum level of inflammatory eytokine, reverse ventricu- lar remodeling and reduce adverse cardiovascular events in patients with HNCM.

关 键 词：卡维地洛 肥厚型心肌病 氧化应激 炎症 心室重构 

分 类 号：R542.2[医药卫生—心血管疾病]